Key regions: Europe, India, Canada, Italy, South Korea
Bronchodilator drugs are widely used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Chile, the market for bronchodilator drugs has been showing steady growth in recent years.
Customer preferences: Chile has a high prevalence of respiratory diseases, which has led to an increase in demand for bronchodilator drugs. The aging population and exposure to air pollution are among the main factors contributing to the high prevalence of respiratory diseases in the country. As a result, there is a growing demand for bronchodilator drugs that can provide quick relief from symptoms such as shortness of breath and wheezing.
Trends in the market: The bronchodilator drugs market in Chile is primarily driven by the increasing prevalence of respiratory diseases. The market is dominated by short-acting beta-agonists (SABAs) and long-acting beta-agonists (LABAs), which are the most commonly prescribed bronchodilator drugs in the country. The demand for combination therapies, which combine bronchodilators with other drugs such as corticosteroids, has also been increasing in recent years.
Local special circumstances: One of the unique features of the bronchodilator drugs market in Chile is the high level of competition among local and international pharmaceutical companies. The market is highly fragmented, with several small and medium-sized players competing with multinational companies. This has led to intense price competition, which has benefited consumers but has put pressure on profit margins for drug manufacturers.
Underlying macroeconomic factors: The Chilean economy has been growing steadily in recent years, which has led to an increase in disposable income and healthcare spending. The government has also been investing in healthcare infrastructure and expanding access to healthcare services, which has contributed to the growth of the bronchodilator drugs market. However, the market is also subject to regulatory risks, as the government has been implementing price controls on certain drugs in an effort to control healthcare costs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
